Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 11/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102394 | 0.86 | P2RX4 (0.50) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL18926940 | 0.76 | P2RX4 (0.44) | P2RX4P2RX1P2RX3P2RX7SMN1; SMN2 | |
| SCHEMBL25933915 | 0.74 | SLC22A3 (0.48) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL10105334 | 0.74 | MAPT (0.42) | P2RX4P2RX1P2RX3P2RX7SMN1; SMN2 | |
| SCHEMBL21439922 | 0.73 | HTR1A (0.50) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL10086947 | 0.71 | MAPT (0.54) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL14299551 | 0.71 | P2RX4 (0.44) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL22739038 | 0.70 | SLC22A3 (0.48) | P2RX4P2RX1P2RX3P2RX7SLC22A3 | |
| SCHEMBL18136099 | 0.69 | P2RX4 (0.44) | P2RX4P2RX1P2RX3P2RX7SMN1; SMN2 | |
| SCHEMBL22739278 | 0.69 | SMN1; SMN2 (0.38) | P2RX4P2RX1P2RX3P2RX7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018315-B2 | Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018315-B2 | Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230242969-A1 | PEPTIDE NUCLEIC ACID FUNCTIONALIZED HYDROGEL MICRONEEDLES FOR SAMPLING AND DETECTION OF INTERSTITIAL FLUID NUCLEIC ACIDS | HOWARD HUGHES MEDICAL INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230242969-A1 | PEPTIDE NUCLEIC ACID FUNCTIONALIZED HYDROGEL MICRONEEDLES FOR SAMPLING AND DETECTION OF INTERSTITIAL FLUID NUCLEIC ACIDS | HOWARD HUGHES MEDICAL INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20200377929-A1 | PEPTIDE NUCLEIC ACID FUNCTIONALIZED HYDROGEL MICRONEEDLES FOR SAMPLING AND DETECTION OF INTERSTITIAL FLUID NUCLEIC ACIDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-12-03 | — | — | US | disclosed |
| US-20170216332-A1 | SMALL MOLECULE ANTI-SCARRING AGENTS | UNIVERSITY OF ROCHESTER (US) | 2017-08-03 | — | — | US | disclosed |
| US-20130237539-A1 | Compounds and Compositions for Treating Cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130203757-A1 | Compounds And Compositions For Treating Cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2013-08-08 | — | — | US | disclosed |
| US-8349832-B2 | Compounds and compositions for treating cancer | Canthera Therapeutics (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120157455-A1 | Compounds And Compositions For Treating Cancer | CANTHERA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110053938-A1 | Compounds and Compositions For Treating Cancer | CANTHERA THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2007034616-A1 | TWO-PHOTON-ABSORBING RECORDING MEDIUM, TWO-PHOTON-ABSORBING RECORDING/REPRODUCING METHOD, AND TWO-PHOTON-ABSORBING RECORDING/REPRODUCING APPARATUS | FUJIFILM CORPORATION (JP) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216332-A1 | SMALL MOLECULE ANTI-SCARRING AGENTS | COLGALT1, MMP1, FIBP | P2RX4 4792/4885P2RX1 4745/4885P2RX3 4734/4885 |
| US-20130203757-A1 | Compounds And Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | P2RX4 2628/4885P2RX1 2241/4885P2RX3 1730/4885 |
| US-20110053938-A1 | Compounds and Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | P2RX4 2628/4885P2RX1 2241/4885P2RX3 1730/4885 |
| US-20130237539-A1 | Compounds and Compositions for Treating Cancer | NQO1, HCCS, TXNRD2 | P2RX4 2628/4885P2RX1 2241/4885P2RX3 1730/4885 |
| US-20120157455-A1 | Compounds And Compositions For Treating Cancer | NQO1, HCCS, TXNRD2 | P2RX4 2628/4885P2RX1 2241/4885P2RX3 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.